Andrea P.
- Country
- Italy
- Department
- SCDU Ematologia
Research Overview
- INCB 50465-801: A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Parsaclisib (INCB050465)
- Phase 3 Randomized Open‑Label Study of Elritercept Versus Epoetin Alfa for Anemia in ESA‑Naïve Adults with Lower‑Risk Myelodysplastic Syndromes Requiring RBC Transfusions
- Phase 3 Randomized Double‑Blind Study of Pelabresib (DAK539) Plus Ruxolitinib vs Placebo + Ruxolitinib in JAK‑Inhibitor‑Naive Adults with Myelofibrosis
Data & Insights
Has run more than one trial at 215 of 394 partner sites.
Specializations
Myeloid Disorders
The investigator specializes in treating various myeloid neoplasms and related conditions, with particular focus on myelofibrosis, myelodysplastic syndromes, and chronic myeloid leukemia.
- Primary and Secondary Myelofibrosis
- Higher-risk and Lower-risk MDS
- BCR-ABL1+ Chronic Myeloid Leukemia
- Polycythemia Vera
Works with novel therapeutic approaches including JAK inhibitors and targeted molecular therapies.
Autoimmune Blood Disorders
Focuses on treating various autoimmune conditions affecting blood cells, particularly immune thrombocytopenia and autoimmune hemolytic anemia.
- Primary Immune Thrombocytopenia (ITP)
- Warm Autoimmune Hemolytic Anemia
- Autoimmune Cytopenias
- Cold Agglutinin Disease
Employs innovative immunomodulatory treatments and targeted therapies.
Rare Blood Conditions
Investigates treatments for uncommon hematologic disorders, including hypereosinophilic syndrome and systemic mastocytosis.
- Hypereosinophilic Syndrome (HES)
- Indolent Systemic Mastocytosis
- Mast Cell Activation Syndrome
Specializes in developing treatment strategies for challenging and rare hematologic conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.